References
- RigelDSEpidemiology of melanomaSemin Cutan Med Surg201029420420921277533
- JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
- AlgaziAPSoonCWDaudAITreatment of cutaneous melanoma: current approaches and future prospectsCancer Manag Res2010219721121188111
- CalifanoJNanceMMalignant melanomaFacial Plast Surg Clin North Am200917333734819698915
- PetrescuICondreaCAlexandruADiagnosis and treatment protocols of cutaneous melanoma: latest approach 2010Chirurgia (Bucur)2010105563764321141087
- National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncologyMelanoma Version 42011
- Intron® (Product information)Kenilworth, NJSchering-Plough Corporation2009
- KirkwoodJMManolaJIbrahimJSondakVErnstoffMSRaoUA pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanomaClin Cancer Res20041051670167715014018
- DavisKLMitraDKotapatiSIbrahimRWolchokJDDirect economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked databaseAppl Health Econ Health Policy200971314119558193
- KotapatiSDavisKLMitraDTreatment patterns in high risk and metastatic melanoma: Evidence from linked electronic medical records and administrative claims dataJ Clin Oncol200826Suppl Abstr 17540
- RaySTunceliAGanguliSEconomic burden of metastatic melanoma in a commercially insured US populationJ Clin Oncol2010Suppl Abstr e19000
- HansenLGChangSHealth research data for the real worldThe Thomson Reuters MarketScan® DatabasesAnn Arbor, MIThomson Reuters2010
- US Bureau of Labor StatisticsConsumer price index, 2011 Available at: http://www.bls.gov/cpi/Accessed May 8, 2012
- KirkwoodJMStrawdermanMHErnstoffMSSmithTJBordenECBlumRHInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol19961417178558223
- AgarwalaSSLeeSJFlahertyLESmylieMRandomized Phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E1697)Abstract presented at the American Society of Clinical Oncology annual meetingChicago, ILJune 3–7, 2011
- KirkwoodJMBenderCAgarwalaSMechanisms and management of toxicities associated with high-dose interferon alfa-2b therapyJ Clin Oncol200220173703371812202672
- EggermontAMSuciuSSantinamiMAdjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trialLancet2008372963311712618620949
- TsaoHRogersGSSoberAJAn estimate of the annual direct cost of treating cutaneous melanomaJ Am Acad Dermatol1998385 Pt 16696809591809
- AlexandrescuDTMelanoma costs: a dynamic model comparing estimated overall costs of various clinical stagesDermatol Online J200915111